# 医院获得性感染控制市场 > 医院获得性感染控制市场研究报告：按感染类型（手术部位感染、导管相关尿路感染、肺炎、艰难梭状芽胞杆菌感染、中心静脉导管相关血流感染）、按病原体类型（细菌、病毒、真菌、寄生虫）、按控制措施（抗生素、消毒剂、灭菌剂、隔离、疫苗接种）、按最终用户（医院、诊所、长期护理设施、门诊手术中心）、按技术（紫外线消毒、负压隔离、自动洗手消毒器、抗微生物涂层、即时诊断）以及按地区（北美、欧洲、南美、亚太、中东和非洲） - 增长前景与行业预测2025至2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 2.87% - **2024:** $ 5.37 Billion - **2025:** $ 5.52 Billion - **2035:** $ 7.33 Billion - **Key Players:** Johnson & Johnson (US), 3M (US), Medtronic (US), Becton Dickinson and Company (US), Stryker Corporation (US), Getinge AB (SE), Ecolab Inc. (US), Halyard Health (US), Cardinal Health (US) **Report ID:** MRFR/HC/28166-HCR · **Pages:** 128 · **Author:** Rahul Gotadki · **Last Updated:** October 17, 2026 **URL:** https://www.marketresearchfuture.com/reports/hospital-acquired-infection-control-market-29899 --- ## Market Summary ## **Hospital Acquired Infection Control Market Overview** As per MRFR analysis, the Hospital Acquired Infection Control Market Size was estimated at 5.24 (USD Billion) in 2023. The Hospital Acquired Infection Control Market Industry is expected to grow from 5.37 (USD Billion) in 2024 to 6.74 (USD Billion) by 2032. The Hospital Acquired Infection Control Market CAGR (growth rate) is expected to be around 2.87% during the forecast period (2024 - 2032). ### **Key Hospital-acquired Infection Control Market Trends Highlighted** Key market drivers for Hospital-acquired Infection Control include increasing healthcare-associated infections, growing awareness of infection prevention practices, and stringent government regulations.Opportunities lie in the development of innovative technologies, such as antimicrobial surfaces, and the expansion of infection control programs in developing countries.Recent trends show a rise in the use of artificial intelligence (AI) and machine learning (ML) for infection surveillance and predictive modeling. Source Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ## **Hospital-acquired Infection Control Market Drivers** ### **Growing Prevalence of Healthcare-Associated Infections (HAIs)** Healthcare-associated infections (HAIs) are a major  health concern, affecting millions of patients each year. HAIs are infections that are acquired during the course of receiving medical care, and they can range from minor skin infections to life-threatening sepsis. The growing prevalence of HAIs is a major driver of the  Hospital-acquired Infection control market. As the number of HAIs increases, so does the need for effective infection control measures.This is driving demand for a wide range of infection control products and services, including disinfectants, personal protective equipment (PPE), and surveillance systems. The rising prevalence of HAIs is due to a number of factors, including the increasing use of invasive medical procedures, the growing number of immunocompromised patients, and the emergence of new and more resistant pathogens. HAIs are a particular problem in hospitals, where patients are often more vulnerable to infection due to their weakened immune systems. The economic burden of HAIs is also a major driver of the  Hospital-acquired Infection control market. HAIs can lead to longer hospital stays, increased healthcare costs, and even death. In the United States, HAIs are estimated to cost the healthcare system billions of dollars each year. The growing prevalence of HAIs, the increasing economic burden of HAIs, and the need for effective infection control measures are all driving the growth of the  Hospital-acquired Infection control market. This market is expected to continue to grow in the coming years as the healthcare industry focuses on improving patient safety and reducing the incidence of HAIs. Some of the key players in the  Hospital-acquired Infection control market include 3M, BD, Cardinal Health, Ecolab, and Getinge.These companies offer a wide range of infection control products and services, including disinfectants, PPE, and surveillance systems. The  Hospital-acquired Infection control market is a complex and dynamic market. The market is driven by a number of factors, including the growing prevalence of HAIs, the increasing economic burden of HAIs, and the need for effective infection control measures.The market is expected to continue to grow in the coming years as the healthcare industry focuses on improving patient safety and reducing the incidence of HAIs. ### **Increasing Adoption of Advanced Infection Control Technologies** The increasing adoption of advanced infection control technologies is another major driver of the  Hospital-acquired Infection control market. These technologies include automated hand hygiene dispensers, UV disinfection systems, and rapid diagnostic tests. These technologies are helping to improve infection control practices and reduce the incidence of HAIs. Automated hand hygiene dispensers are touchless dispensers that dispense soap or sanitizer without the need for the user to touch the dispenser.This helps to reduce the spread of bacteria and viruses, as users do not have to touch a potentially contaminated surface. UV disinfection systems use ultraviolet light to kill bacteria and viruses. These systems can be used to disinfect surfaces, equipment, and even the air. UV disinfection systems are becoming increasingly popular in healthcare settings, as they are effective in killing a wide range of pathogens. Rapid diagnostic tests can quickly and accurately identify the presence of bacteria or viruses.This information can help clinicians to make faster and more informed decisions about patient care. Rapid diagnostic tests are also helping to reduce the use of antibiotics, as they can identify infections that do not require antibiotic treatment. The increasing adoption of advanced infection control technologies is helping to improve infection control practices and reduce the incidence of HAIs. This is a major driver of the  Hospital-acquired Infection control market, and it is expected to continue to drive growth in the coming years. ### **Government Regulations and Initiatives** Government regulations and initiatives are also playing a role in driving the growth of the  Hospital-acquired Infection control market. Many governments have implemented regulations that require hospitals to adopt certain infection control measures. These regulations are helping to improve infection control practices and reduce the incidence of HAIs. In addition, many governments are providing funding for infection control research and development. This funding is helping to drive the development of new and innovative infection control products and services. Government regulations and initiatives are helping to create a more favorable environment for the growth of the  Hospital-acquired Infection control market.These regulations and initiatives are helping to improve infection control practices, reduce the incidence of HAIs, and drive the development of new and innovative infection control products and services. ## **Hospital-acquired Infection Control Market Segment Insights** ### **Hospital-acquired Infection Control Market Type of Infection Insights** The  Hospital-acquired Infection Control Market is expected to witness robust growth in the coming years, driven by the increasing prevalence of healthcare-associated infections (HAIs). HAIs are a major public health concern, affecting millions of patients worldwide and leading to significant morbidity and mortality.The market for Hospital-acquired Infection Control is segmented into various categories, including type of infection, end-user, and region. Based on the type of infection, the market is segmented into surgical site infections, catheter-associated urinary tract infections, pneumonia, Clostridioides difficile infection, and central line-associated bloodstream infections. [Surgical Site Infections](../../../reports/surgical-site-infection-control-market-7830) (SSIs) are the most common type of HAI, accounting for approximately 30% of all HAIs. SSIs can occur at the site of any surgical incision and can range in severity from minor skin infections to life-threatening deep tissue infections.The market for SSI control is expected to reach USD 4.5 billion by 2024, growing at a CAGR of 7.5%. Catheter-Associated Urinary Tract Infections (CAUTIs) Catheter-Associated Urinary Tract Infections (CAUTIs) are the second most common type of HAI, accounting for approximately 20% of all HAIs. CAUTIs are caused by bacteria that enter the urinary tract through a catheter, which is a tube inserted into the bladder to drain urine. The  market for CAUTI control is expected to reach USD 2.8 billion by 2024, growing at a CAGR of 6.8%.Pneumonia is a lung infection that can be caused by bacteria, viruses, or fungi. Pneumonia is a leading cause of death in hospitals, accounting for approximately 10% of all HAIs. The  market for pneumonia control is expected to reach USD 3.2 billion by 2024, growing at a CAGR of 7.2%. Clostridioides difficile Infection (CDI) Clostridioides difficile Infection (CDI) is a bacterial infection that causes severe diarrhea. CDI is a common HAI, affecting approximately 5% of hospitalized patients. The  market for CDI control is expected to reach USD 1.5 billion by 2024, growing at a CAGR of 6.5%.Central Line-Associated Bloodstream Infections (CLABSIs) Central Line-Associated Bloodstream Infections (CLABSIs) are bloodstream infections that are caused by bacteria that enter the bloodstream through a central line, which is a tube inserted into a large vein in the chest or neck.CLABSIs are serious HAIs with a mortality rate of up to 25%. The  market for CLABSI control is expected to reach USD 1.2 billion by 2024, growing at a CAGR of 6.3%. **Source Primary Research, Secondary Research, MRFR Database and Analyst Review** ### **Hospital-acquired Infection Control Market Pathogen Type Insights** The  Hospital-acquired Infection Control Market segmentation by Pathogen Type includes Bacteria, Viruses, Fungi, and Parasites. Among these, Bacteria held the dominant market share in 2023 and is expected to maintain its dominance throughout the forecast period. The high prevalence of bacterial infections in hospitals, such as MRSA and C. difficile, is a major factor driving the growth of this segment. Viruses are also a significant segment, with increasing incidences of viral infections such as influenza and norovirus in healthcare settings.Fungi and parasites account for a smaller share of the market but are still important contributors to hospital-acquired infections. The increasing focus on infection prevention and control measures is expected to drive the growth of the Hospital-acquired Infection Control Market over the forecast period. ### **Hospital-acquired Infection Control Market Control Measure Insights** The Control Measure segment of the  Hospital-acquired Infection Control Market is anticipated to exhibit robust growth, driven by increasing awareness about healthcare-associated infections (HAIs) and the adoption of advanced infection control practices. Antibiotics, antiseptics, and disinfectants remain the mainstay of infection control, with the  antibiotics market projected to reach USD 55.9 billion by 2024. Antiseptics and disinfectants are also expected to witness significant demand, owing to their efficacy in preventing the spread of HAIs. Isolation, including the use of negative pressure rooms and cohorts, is another key control measure. Vaccination plays a crucial role in preventing HAIs, with vaccines available for diseases such as influenza, measles, and hepatitis B.The  Hospital-acquired Infection Control Market is expected to witness substantial growth in the coming years, driven by rising healthcare expenditure, technological advancements, and increasing demand for effective infection control solutions. ### **Hospital-acquired Infection Control Market End User Insights** The Hospital-acquired Infection Control Market is segmented by End User into Hospitals, Clinics, Long-Term Care Facilities, and Ambulatory Surgical Centers. Hospitals hold the largest market share due to the high prevalence of HAIs in these settings. The increasing number of surgical procedures, longer hospital stays, and the presence of vulnerable patients contribute to the high demand for infection control measures in hospitals. Clinics are expected to witness significant growth over the forecast period due to the rising number of outpatient procedures and the growing emphasis on infection prevention in ambulatory settings. Long-Term Care Facilities are anticipated to experience steady growth due to the increasing number of elderly patients and the rising prevalence of chronic diseases that require long-term care. Ambulatory Surgical Centers are expected to witness moderate growth as they offer a cost-effective and convenient alternative to traditional hospital settings for certain surgical procedures. ### **Hospital-acquired Infection Control Market Technology Insights** The  Hospital-acquired Infection Control Market is segmented by technology into Ultraviolet Light Disinfection, Negative Pressure Isolation, Automated Hand Hygiene Dispensers, Antimicrobial Coatings, and Point-of-Care Diagnostics. The Ultraviolet Light Disinfection segment held the largest market share in 2023, owing to its increasing adoption in hospitals to reduce the risk of HAIs. The Negative Pressure Isolation segment is also expected to witness significant growth, driven by the rising demand for isolation rooms to prevent the spread of airborne infections. Automated Hand Hygiene Dispensers are gaining popularity due to their ability to promote hand hygiene compliance among healthcare workers. Antimicrobial Coatings are being increasingly used to prevent the growth of microorganisms on hospital surfaces, while Point-of-Care Diagnostics are being adopted to enable rapid and accurate diagnosis of HAIs. ### **Hospital-acquired Infection Control Market Regional Insights** The  Hospital-acquired Infection Control Market is segmented into regions comprising 'North America', 'Europe', 'APAC', 'South America', and 'MEA'. Regionally, North America is expected to hold the largest market share with an expected valuation of 10.25 billion USD by 2024. The region's market growth is attributed to the increasing prevalence of hospital-acquired infections (HAIs), stringent government regulations related to infection control, and the presence of advanced healthcare infrastructure. Europe is anticipated to follow North America with the second-largest market share of 6.1 Billion USD in 2024 due to factors such as rising healthcare expenditure, growing awareness of HAIs, and the adoption of advanced technologies for infection control. APAC is projected to experience significant market growth at a CAGR of 8.25% during the forecast period, owing to the increasing number of hospitals, rising patient population, and expanding healthcare facilities in the region. South America and MEA are expected to witness steady growth in the Hospital-acquired Infection Control Market, with a focus on strengthening infection control practices and improving patient safety.   Source Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ## **Hospital-acquired Infection Control Market Key Players and Competitive Insights** Major players in the Hospital-acquired Infection Control Market industry are focusing on developing innovative products and solutions to meet the evolving needs of the market. Leading Hospital-acquired Infection Control Market players are investing in research and development to enhance the efficacy and safety of their products. The Hospital-acquired Infection Control Market's development of new technologies, such as antimicrobial coatings and rapid diagnostic tests, is driving the growth of the market. Merger and acquisition activities are also prevalent in the Hospital-acquired Infection Control Market Competitive Landscape, as companies seek to expand their product portfolios. Stryker is one of the prominent players in the Hospital-acquired Infection Control Market. The company offers a comprehensive range of products and services for infection prevention and control, including surgical instruments, surgical gowns, and disinfectants. Stryker's commitment to innovation has led to the development of several cutting-edge technologies, such as the SurgiCount+ Surgical Sponge System and the Neptune Washer-Disinfector. These technologies have been designed to improve patient safety and reduce the risk of infections. 3M is another leading company in the Hospital-acquired Infection Control Market. The company offers a wide range of products for infection prevention and control, including hand hygiene products, disinfectants, and surgical drapes. 3M's focus on research and development has resulted in the development of innovative products, such as the Steri-Drape and Steri-Strip products. These products have been designed to improve patient safety and reduce the risk of infections. ### **Key Companies in the Hospital-Acquired Infection Control Market Include** - BD - Medtronic - Sterigenics - [**Baxter International**](https://www.baxter.in/healthcare-professionals/critical-care) - Steris - Getinge - Kimberly-Clark - Ecolab - Johnson Johnson - Cardinal Health - Sotera Health - Stryker - 3M ## Hospital-acquired Infection Control Industry Developments - **Q2 2024: STERIS Announces FDA Clearance of V-PRO® maX 2 Low Temperature Sterilization System** STERIS received FDA clearance for its V-PRO® maX 2 Low Temperature Sterilization System, designed to help healthcare facilities reduce the risk of hospital-acquired infections by improving sterilization of medical devices. - **Q2 2024: Cantel Medical Launches New ADVANTAGE PLUS™ Pass-Thru Automated Endoscope Reprocessor** Cantel Medical announced the launch of its ADVANTAGE PLUS™ Pass-Thru Automated Endoscope Reprocessor, a new device aimed at enhancing infection prevention in hospitals by automating and improving endoscope reprocessing. - **Q1 2024: 3M Introduces 3M™ Clean-Trace™ Hygiene Monitoring and Management System for Healthcare Facilities** 3M launched the Clean-Trace™ Hygiene Monitoring and Management System, a new product designed to help hospitals monitor and manage surface cleanliness, supporting infection control efforts. - **Q2 2024: Getinge acquires Ultra Clean Systems to expand infection control portfolio** Getinge announced the acquisition of Ultra Clean Systems, a U.S.-based manufacturer of ultrasonic cleaning equipment for hospitals, strengthening Getinge’s infection control solutions. - **Q1 2024: Ecolab Launches Next-Generation OxyCide™ Daily Disinfectant Cleaner for Healthcare Facilities** Ecolab introduced a new version of its OxyCide™ Daily Disinfectant Cleaner, formulated to help hospitals reduce the risk of hospital-acquired infections through improved surface disinfection. - **Q2 2024: Metrex Research Launches CaviWipes™ 2.0, an Enhanced Surface Disinfectant for Healthcare Settings** Metrex Research announced the launch of CaviWipes™ 2.0, a new surface disinfectant wipe designed to provide faster and broader-spectrum efficacy against pathogens responsible for hospital-acquired infections. - **Q1 2024: Stryker Launches SurgiCount360™ Sterile Processing Platform** Stryker launched the SurgiCount360™ platform, a new sterile processing solution aimed at improving instrument tracking and reducing the risk of surgical site infections in hospitals. - **Q2 2024: Advanced Sterilization Products Announces Partnership with Medline to Expand Access to Infection Prevention Technologies** Advanced Sterilization Products (ASP) entered into a partnership with Medline to distribute ASP’s infection prevention technologies to a broader range of healthcare facilities. - **Q1 2024: Belimed Opens New Manufacturing Facility in Charleston, South Carolina** Belimed, a provider of infection control solutions, opened a new manufacturing facility in Charleston, SC, to expand production capacity for sterilization and disinfection equipment. - **Q2 2024: Tru-D SmartUVC Launches Next-Generation UVC Disinfection Robot for Hospitals** Tru-D SmartUVC introduced a new UVC disinfection robot designed to automate and enhance the disinfection of hospital rooms, supporting efforts to reduce hospital-acquired infections. - **Q1 2024: PDI Healthcare Launches Sani-Cloth® Prime Germicidal Disposable Wipe** PDI Healthcare launched the Sani-Cloth® Prime Germicidal Disposable Wipe, a new product aimed at providing hospitals with a faster-acting and broader-spectrum disinfectant wipe for infection control. - **Q2 2024: UV Angel Announces FDA Clearance for UV-C Air Disinfection System for Healthcare Environments** UV Angel received FDA clearance for its UV-C air disinfection system, designed to reduce airborne pathogens in hospitals and support infection control initiatives. ## **Hospital-acquired Infection Control Market Segmentation Insights** ### **Hospital-acquired Infection Control Market Type of Infection Outlook** - Surgical Site Infections - Catheter-Associated Urinary Tract Infections - Pneumonia - Clostridioides difficile Infection - Central Line-Associated Bloodstream Infections ### **Hospital-acquired Infection Control Market Pathogen Type Outlook** - Bacteria - Viruses - Fungi - Parasites ### **Hospital-acquired Infection Control Market Control Measure Outlook** - Antibiotics - Antiseptics - Disinfectants - Isolation - Vaccination ### **Hospital-acquired Infection Control Market End User Outlook** - Hospitals - Clinics - Long-Term Care Facilities - Ambulatory Surgical Centers ### **Hospital-acquired Infection Control Market Technology Outlook** - Ultraviolet Light Disinfection - Negative Pressure Isolation - Automated Hand Hygiene Dispensers - Antimicrobial Coatings - Point-of-Care Diagnostics ### **Hospital-acquired Infection Control Market Regional Outlook** - North America - Europe - South America - Asia Pacific - Middle East and Africa ## Market Drivers ### Growing Awareness of Patient Safety 医院获得性感染控制市场正在增长，这一增长受到医疗提供者和患者对患者安全日益关注的推动。随着医院获得性感染的影响被越来越广泛地认识，优先考虑感染预防策略的努力也在加大。针对医疗专业人士和公众的教育倡议和活动正在促进安全文化的形成，这反过来又导致对感染控制技术和实践的更高投资。最近的调查表明，越来越多的患者在选择医疗设施时考虑感染率，这进一步强调了强有力的感染控制措施的重要性。这种高度的意识可能会推动市场对创新解决方案的需求。 ### Regulatory Compliance and Standards 医院获得性感染控制市场受到卫生当局制定的严格监管合规和标准的显著影响。监管机构越来越要求医院实施全面的感染控制计划，包括定期监测和报告感染率。这种监管关注不仅迫使医疗设施投资于先进的感染控制解决方案，还促进了问责制和透明度的文化。数据显示，遵守这些规定的医院经历了较低的医院获得性感染率，从而改善了患者的结果。随着合规性成为医院运营的关键因素，预计对有效感染控制措施的需求将上升，从而推动市场的增长。 ### Shift Towards Value-Based Healthcare 医院获得性感染控制市场受到向基于价值的医疗转变的影响，该转变强调护理质量和患者结果。这一范式转变鼓励医疗提供者专注于减少医院获得性感染，以改善整体患者满意度并降低与延长住院相关的成本。随着报销模式越来越多地将财务激励与感染控制绩效挂钩，医院被迫采用有效的感染预防策略。数据显示，拥有强大感染控制计划的设施不仅提高了患者安全性，还实现了更好的财务结果。因此，随着医疗系统适应这一不断发展的环境，对创新感染控制解决方案的需求可能会增长。 ### Technological Innovations in Infection Control 医院获得性感染控制市场正在见证旨在增强感染预防措施的技术创新激增。先进的消毒技术，如紫外线（UV）光消毒和自动清洁系统，正变得越来越普遍。这些创新不仅提高了感染控制协议的有效性，还减少了与传统清洁方法相关的劳动强度。根据最近的数据，这些技术的采用导致各种医疗环境中的感染率报告下降了多达30%。随着医院努力保持高标准的患者安全，尖端技术的整合可能在塑造感染控制实践的未来中发挥关键作用。 ### Rising Incidence of Hospital-Acquired Infections 医院获得性感染控制市场受到医院获得性感染（HAIs）发生率上升的推动，这对患者安全和医疗质量构成了严重威胁。来自卫生组织的数据表明，每年有数百万患者受到HAIs的影响，导致发病率增加、住院时间延长和医疗成本上升。这一令人担忧的趋势促使医疗设施优先考虑感染控制措施，导致对有效解决方案的需求激增。医院现在正在投资于全面的感染预防计划，包括监测系统和员工培训，以降低与HAIs相关的风险。随着这些感染的流行率持续上升，感染控制解决方案的市场预计将显著扩展。 ## Future Outlook 医院获得性感染控制市场预计在2024年至2035年间以2.87%的年均增长率增长，受技术进步、监管支持和对感染控制意识的提高推动。 到2035年，医疗获得性感染控制市场预计将实现强劲增长，反映全球感染控制措施的增强。 **New opportunities:** - 医疗设备的先进抗菌涂层开发 到2035年，市场预计将实现强劲增长，反映全球感染控制措施的增强。 ## Segment Insights ### 按感染类型：手术部位感染（最大）与艰难梭状芽胞杆菌感染（增长最快） 医院获得性感染控制市场展示了多种感染类型，其中手术部位感染（SSI）占据最大的市场份额。SSI通常占据医疗相关感染的显著部分，因为频繁的手术程序会导致这种情况，并且它们需要严格的感染控制协议。在SSI之后，导尿管相关的[尿路感染](https://www.marketresearchfuture.com/reports/urinary-tract-infection-market-6138)和中心静脉导管相关的血流感染也代表了重要的细分市场，尽管它们在医院获得性感染控制市场份额动态中落后于SSI。艰难梭状芽胞杆菌感染正逐渐成为一个关键问题，因其日益增加的流行程度和对患者健康结果的影响而受到关注。 感染类型的增长趋势反映了不断发展的医疗实践、技术进步以及对感染预防的认识提高。手术部位感染继续主导，因为其关键性质和对改进手术协议的推动。与此同时，艰难梭状芽胞杆菌感染被定位为增长最快的细分市场，原因在于抗生素耐药性的上升和对有效感染控制措施的高度重视，这推动了新治疗策略的发展。这一演变至关重要，因为医疗提供者努力提高患者安全性并降低整体感染率。 手术部位感染（主导）与艰难梭状芽胞杆菌感染（新兴） 手术部位感染（SSI）被认为是医院获得性感染中最主导的类别，源于破坏皮肤完整性的手术程序。这些感染可能导致更长的住院时间、增加的医院获得性感染成本，甚至严重并发症。医疗机构越来越重视减轻SSI的协议，包括严格的消毒实践和改进的手术技术。相反，艰难梭状芽胞杆菌感染代表了一种新兴威胁，主要与抗生素使用相关，并导致严重的胃肠道并发症。其快速增长可归因于医院报告的病例显著增加，促使需要创新的控制策略和预防措施以有效应对其传播。这种主导感染类型与新兴感染类型的对比突显了医疗环境中感染模式的动态特性。 ### 按病原体类型：细菌（最大）与病毒（增长最快） 在医院获得性感染控制市场中，病原体类型的分布显示出细菌的显著主导地位。细菌由于在医院环境中的普遍性和对有效感染控制措施的迫切需求而占据最大的细分市场。细菌感染的广泛性及其韧性特征需要在医疗设施中持续监测和控制策略。 相反，病毒正在成为医院获得性感染控制市场中增长最快的细分市场。这一增长可归因于病毒感染的激增，包括流感和冠状病毒，这提高了医疗提供者和机构的认识。趋势表明，针对病毒的强有力感染控制协议正变得至关重要，特别是针对最近的全球健康危机。 细菌（主导）与病毒（新兴） 细菌目前主导医院获得性感染控制市场，由多种感染性病原体驱动，如耐甲氧西林金黄色葡萄球菌（MRSA）和艰难梭状芽胞杆菌。这些病原体对患者安全构成重大风险，导致医院优先考虑有效的控制措施，包括先进的清洁协议、抗微生物管理和监测系统。因此，对细菌感染控制的投资反映了其在保护患者福利中的关键性质。相反，病毒被定位为新兴细分市场，反映出发生率的增加和不断演变的菌株，这对当前的感染控制措施构成挑战。对疫苗接种、快速诊断和医院环境中病毒传播教育的重视突显了管理病毒感染的迫切需求。 ### 按控制措施：抗菌剂（最大）与消毒剂（增长最快） 在医院获得性感染控制市场中，控制措施的市场份额分布显示抗菌剂占据最大份额，主要由于其在手术前准备和伤口护理中的广泛使用。消毒剂虽然目前份额较小，但随着医疗设施越来越多地采用先进的清洁协议以对抗感染，正在迅速获得关注，这得益于对卫生和预防措施认识的提高。将消毒剂纳入常规安全措施对于改善医疗结果和维持感染控制协议至关重要。 增长趋势表明，医疗环境中优化感染控制措施的强烈关注，导致在抗菌剂和消毒剂方面进行重大研究和开发。医院获得性感染（HAI）的负担加重以及医院卫生的严格规定推动了对有效控制措施的需求。增长的关键驱动因素包括消毒剂配方的技术进步和对患者安全的日益重视，因为医院努力降低感染率并提高整体医疗质量。 抗菌剂（主导）与消毒剂（新兴） 抗菌剂已在医院获得性感染控制市场中确立了主导地位，因为它们在手术过程中和[伤口管理](https://www.marketresearchfuture.com/reports/wound-management-market-42371)中防止感染的关键作用。它们对广谱病原体的有效性以及在医疗专业人员中的接受度标志着其重要性。相反，消毒剂正在成为感染控制策略中的关键元素，特别是在医院环境中。它们在创新、高效和环保配方方面的快速发展表明其日益重要性。表面消毒剂的采用正在上升，推动了对严格清洁协议的需求，以防止HAI。这两个细分市场都是必不可少的，但它们各自发挥着不同的作用，突显了感染控制所需的多方面方法。 ### 按最终用户：医院（最大）与长期护理设施（增长最快） 在医院获得性感染控制市场中，医院占据最大的份额，因为它们是感染普遍且对患者构成重大风险的主要医疗环境。它们的广泛运营和高患者周转率使其在优先考虑感染控制措施方面至关重要。相反，长期护理设施虽然是一个较小的细分市场，但随着老龄化人口对持续医疗服务的需求增加，正在迅速增长，从而提高了对这些环境中感染控制实践的关注。 医院：（主导）与诊所（新兴） 医院在感染控制工作中处于中心地位，因其规模和复杂性。它们通常有更多的资源用于感染预防和控制（IPC）协议、技术升级和员工培训。手术程序和患者入院人数的增加直接与医院获得性感染（HAI）的风险增加相关，因此需要严格的措施。相反，诊所虽然在医院获得性感染控制市场中正在新兴，但往往专注于门诊护理，可能没有与医院相同的资源或复杂性。它们对IPC的日益关注，受到防止HAI的需求的影响，正在促进创新和扩展，尽管与医院环境相比，速度较慢。 ### 按技术：紫外线消毒（最大）与自动手卫生分配器（增长最快） 医院获得性感染控制市场受到几项关键技术的显著影响，其中紫外线消毒因其在消灭医院表面微生物方面的有效性而处于领先地位。紧随其后，医院获得性感染控制市场还包括负压隔离、抗微生物涂层和即时诊断，每种技术以独特的方式促进感染控制。自动手卫生分配器正在迅速获得关注，因为医疗设施越来越重视卫生协议以防止感染，显示出与已建立技术相伴随的显著增长潜力。 技术：紫外线消毒（主导）与自动手卫生分配器（新兴） 紫外线消毒被认为是医院感染控制中的主导技术，利用紫外线的能力在没有化学剂的情况下消毒空间，使其成为维持无菌环境的首选。对感染病原体的抵抗力使这项技术在高风险区域中至关重要。另一方面，自动手卫生分配器正在成为增强手卫生协议遵守的重要工具。通过内置传感器和快速访问，它们确保医疗人员有效且持续地进行卫生操作，从而减少医院获得性感染。对医院健康和安全的日益关注正在推动对这两种技术的需求，尽管紫外线消毒仍然在医院获得性感染控制市场中处于领先地位。 ## Regional Market Share Analysis 医院获得性感染控制市场分为“北美”、“欧洲”、“亚太”、“南美”和“中东和非洲”五个地区。从区域上看，北美预计将在2024年占据最大的市场份额，预计估值为102.5亿美元。 该地区医院获得性感染控制市场的增长归因于医院获得性感染（HAIs）日益普遍、与感染控制相关的严格政府法规以及先进医疗基础设施的存在。 预计欧洲将紧随北美，其市场份额在2024年为61亿美元，原因包括医疗支出增加、对HAIs的认识提高以及采用先进的感染控制技术。 亚太地区预计将在预测期内以8.25%的年均复合增长率经历显著的外科部位感染控制市场增长，原因是医院数量增加、患者人数上升以及该地区医疗设施的扩展。 南美和中东及非洲预计将在医院获得性感染控制市场中见证稳定增长，重点是加强感染控制实践和改善患者安全。 来源：初级研究、次级研究、市场研究未来数据库和分析师评审 ## Competitive Benchmarking 医院获得性感染控制市场的主要参与者正专注于开发创新产品和解决方案，以满足外科部位感染控制市场不断变化的需求。领先的医院获得性感染控制市场参与者正在投资于研究和开发，以提高其产品的有效性和安全性。 医院获得性感染控制市场新技术的发展，如抗菌涂层和快速诊断测试，正在推动市场的增长。并购活动在医院获得性感染控制市场竞争格局中也很普遍，因为公司寻求扩大其产品组合。 斯特赖克是医院获得性感染控制市场的主要参与者之一。该公司提供全面的感染预防和控制产品和服务，包括外科器械、外科服和消毒剂。 斯特赖克对创新的承诺导致了多个尖端技术的开发，如SurgiCount+外科海绵系统和Neptune清洗消毒机。这些技术旨在提高患者安全并降低感染风险。 3M是医院获得性感染控制市场的另一家领先公司。该公司提供广泛的感染预防和控制产品，包括手部卫生产品、消毒剂和外科覆盖物。 3M对研究和开发的关注导致了创新产品的开发，如Steri-Drape和Steri-Strip产品。这些产品旨在提高患者安全并降低感染风险。 ## Recent News & Developments - **2024年第二季度：STERIS宣布FDA批准V-PRO® maX 2低温灭菌系统** STERIS获得FDA批准其V-PRO® maX 2低温灭菌系统，旨在帮助医疗机构通过改善医疗设备的灭菌来降低医院获得性感染的风险。 - **2024年第二季度：Cantel Medical推出新款ADVANTAGE PLUS™通道自动内窥镜清洗机** Cantel Medical宣布推出其ADVANTAGE PLUS™通道自动内窥镜清洗机，这是一种旨在通过自动化和改善内窥镜清洗来增强医院感染预防的新设备。 - **2024年第一季度：3M推出3M™ Clean-Trace™卫生监测和管理系统，适用于医疗机构** 3M推出了Clean-Trace™卫生监测和管理系统，这是一种新产品，旨在帮助医院监测和管理表面清洁度，支持感染控制工作。 - **2024年第二季度：Getinge收购Ultra Clean Systems以扩展感染控制产品组合** Getinge宣布收购Ultra Clean Systems，这是一家美国医院超声清洗设备制造商，增强了Getinge的感染控制解决方案。 - **2024年第一季度：Ecolab推出新一代OxyCide™日常消毒清洁剂，适用于医疗机构** Ecolab推出了其OxyCide™日常消毒清洁剂的新版本，旨在通过改善表面消毒来帮助医院降低医院获得性感染的风险。 - **2024年第二季度：Metrex Research推出CaviWipes™ 2.0，一种增强型表面消毒剂，适用于医疗环境** Metrex Research宣布推出CaviWipes™ 2.0，这是一种新型表面消毒湿巾，旨在对导致医院获得性感染的病原体提供更快和更广谱的效力。 - **2024年第一季度：斯特赖克推出SurgiCount360™无菌处理平台** 斯特赖克推出了SurgiCount360™平台，这是一种新的无菌处理解决方案，旨在改善器械追踪并降低医院外科部位感染的风险。 - **2024年第二季度：先进灭菌产品宣布与Medline合作，以扩大对感染预防技术的访问** 先进灭菌产品（ASP）与Medline达成合作，向更广泛的医疗机构分发ASP的感染预防技术。 - **2024年第一季度：Belimed在南卡罗来纳州查尔斯顿开设新制造设施** Belimed是一家感染控制解决方案提供商，在南卡罗来纳州查尔斯顿开设了新的制造设施，以扩大灭菌和消毒设备的生产能力。 - **2024年第二季度：Tru-D SmartUVC推出新一代UVC消毒机器人，适用于医院** Tru-D SmartUVC推出了一种新的UVC消毒机器人，旨在自动化和增强医院房间的消毒，支持减少医院获得性感染的努力。 - **2024年第一季度：PDI Healthcare推出Sani-Cloth® Prime杀菌一次性湿巾** PDI Healthcare推出了Sani-Cloth® Prime杀菌一次性湿巾，这是一种新产品，旨在为医院提供更快作用和更广谱的消毒湿巾，以进行感染控制。 - **2024年第二季度：UV Angel宣布FDA批准UV-C空气消毒系统，适用于医疗环境** UV Angel获得FDA批准其UV-C空气消毒系统，旨在减少医院中的空气传播病原体，并支持感染控制倡议。 ## Report Scope | 2024年市场规模 | 53.7（亿美元） | | --- | --- | | 2025年市场规模 | 55.24（亿美元） | | 2035年市场规模 | 73.32（亿美元） | | 年均复合增长率（CAGR） | 2.87%（2025 - 2035） | | 报告覆盖范围 | 收入预测、竞争格局、增长因素和趋势 | | 基准年 | 2024 | | 市场预测期 | 2025 - 2035 | | 历史数据 | 2019 - 2024 | | 市场预测单位 | 亿美元 | | 主要公司简介 | 强生（美国），3M（美国），美敦力（美国），贝克顿·迪金森公司（美国），斯特赖克公司（美国），盖廷公司（瑞典），艾克劳公司（美国），哈利亚德健康（美国），凯迪尔健康（美国） | | 覆盖的细分市场 | 感染类型、病原体类型、控制措施、最终用户、技术、区域 | | 主要市场机会 | 先进灭菌技术的整合增强了医院获得性感染控制市场的感染控制。 | | 主要市场动态 | 日益严格的监管审查和技术进步推动医院获得性感染控制解决方案的创新。 | | 覆盖的国家 | 北美、欧洲、亚太、南美、中东和非洲 | ## Frequently Asked Questions **Q: 2035年医院获得性感染控制市场的预计市场估值是多少？** A: 2035年医院获得性感染控制市场的预计市场估值为73.32亿美元。 **Q: 2024年医院获得性感染控制市场的市场估值是多少？** A: 2024年医院获得性感染控制市场的市场估值为53.7亿美元。 **Q: 2025年至2035年医院获得性感染控制市场的预期年复合增长率是多少？** A: 2025年至2035年医院获得性感染控制市场的预期年复合增长率为2.87%。 **Q: 哪些公司被认为是医院获得性感染控制市场的关键参与者？** A: 医院获得性感染控制市场的关键参与者包括强生公司、3M、美敦力和贝克顿·迪金森公司。 **Q: 2024年医院获得性感染控制市场哪个细分市场的估值最高？** A: 2024年，外科手术部位感染细分市场的估值最高，达到15亿美元。 **Q: 到2035年，导管相关尿路感染市场预计将增长多少？** A: 导管相关尿路感染市场预计将从2024年的12亿美元增长到2035年的16亿美元。 **Q: 到2035年，哪个控制措施细分市场预计将实现显著增长？** A: 消毒剂细分市场预计将从2024年的12亿美元增长到2035年的15亿美元。 **Q: 到2035年，哪个最终用户细分市场预计将拥有最大的市场份额？** A: 医院细分市场预计将拥有最大的市场份额，从2024年的25亿美元增加到2035年的35亿美元。 **Q: 到2035年，哪个技术细分市场预计将经历最多的增长？** A: 抗菌涂层细分市场预计将经历显著增长，从2024年的12亿美元上升到2035年的18亿美元。 **Q: 在医院获得性感染控制市场中，哪个病原体类型细分市场预计将增长最快？** A: 细菌细分市场预计将增长最快，从2024年的15亿美元增加到2035年的20亿美元。 --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/hospital-acquired-infection-control-market-29899*